Reviews/Ssris and Snris/Escitalopram and sertraline have the best efficacy and acceptability profile among antidepressants
· SS-CMP-01 · v2
Borderline: within 4 points of the Doubtful/Refuted boundary, so a re-grade could land either side.
The claim is that two specific drugs, escitalopram and sertraline, are the best of all antidepressants on both how well they work and how well patients tolerate them. To support a statement like that you need a study that lines up all the major antidepressants and ranks them, but no such study in this corpus is of a type the panel could use for scoring. What remains are a handful of smaller comparisons, and they point the other way: where sertraline and escitalopram were tested directly against other drugs, they were no better [2][4], a re-analysis argues apparent differences between antidepressants are largely a statistical artefact [10], and a large comparison found escitalopram caused more weight gain than sertraline [11]. The panel concluded the evidence here does not support a 'best among antidepressants' ranking and in several places works against it.
No admissible study in this corpus ranks the full antidepressant class, so the claim's central comparison is untested here. In the direct comparisons that do exist, sertraline did not differ significantly from bupropion or venlafaxine in outcomes, tolerability or adverse events [2], and escitalopram did not differ from agomelatine [4]. A Monte Carlo simulation found that under a true null one or more false superiority claims arose over 70% of the time, concluding there is little evidence any antidepressant is more effective than another [10]. On tolerability, a 183118-patient emulation estimated escitalopram produced 0.41 kg more 6-month weight gain than sertraline (95% CI, 0.31 to 0.52 kg) [11], while the escitalopram evidence that remains is only versus placebo or a device [14][16]. The contested point: The decisive point is what counts as evidence for a class ranking: the comparative syntheses that could rank the whole field were removed by the study-type filter, leaving only partial head-to-head and placebo-controlled trials. Those surviving comparisons do not favour the two named drugs, and one [11] separates them on tolerability rather than uniting them.
All 18 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Ssris and Snris, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim is a class-wide ranking on two axes, but every comparative evidence synthesis capable of ranking the whole field (Cipriani Cochrane reviews, Kriston NMA) was removed by the study-type filter, and no admissible primary study performs a class-wide comparison. The corpus cannot establish 'best among antidepressants'.
Where admissible head-to-head data exist, they show NO superiority: sertraline did not differ from bupropion or venlafaxine [2], and escitalopram did not differ from agomelatine [4]. This is direct evidence against the claim, not for it.
Where it remains uncertain. The two drugs are claimed to share a best acceptability profile, yet a large comparison put escitalopram behind sertraline on weight gain (0.41 kg difference) [11].
Aleatory
The weight-change estimates rest on follow-up where 6-month adherence ranged from 28% to 41%, adding irreducible variability to the comparison [11].
Epistemic
The corpus contains no admissible study that ranks all antidepressants on efficacy and acceptability, so the claim's core quantity is simply unmeasured here.
Inferential
Inferring a class ranking from single-comparator [4], placebo or device [14] and special-population [16] trials is a leap the designs do not support.
The load-bearing papers from a corpus of 18, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Sertraline shows no superiority over bupropion or venlafaxine head-to-head, counter to a 'best efficacy and acceptability' claim.
“These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events.”
Panel auditInternal validity: high · scope of inference: Second-step treatment in adults with nonpsychotic MDD who had not remitted on or could not tolerate the SSRI citalopram.Key limitations: treatment-resistant population · no escitalopram arm · switch-only design
Escitalopram shows no superiority over agomelatine, undercutting the 'best among antidepressants' framing.
“There was no difference in week 1 changes of interest between agomelatine and escitalopram.”
Panel auditInternal validity: medium · scope of inference: Escitalopram vs agomelatine in outpatients with moderate to severe MDD over 12 weeks.Key limitations: narrow primary endpoint · single comparator · authors note need for additional comparators
The two co-named drugs diverge on a tolerability measure, with escitalopram worse than sertraline.
“Compared with that for sertraline, estimated 6-month weight gain was higher for escitalopram (difference, 0.41 kg [95% CI, 0.31 to 0.52 kg])”
Panel auditInternal validity: medium · scope of inference: Comparative 6-month weight change across eight first-line antidepressants in US EHR patients.Key limitations: observational design · weight is only one acceptability facet · low follow-up adherence · incomplete weight measures
Directly challenges the premise that any specific antidepressant, including the two named, is best.
“there is little evidence in these trials that any antidepressant is more effective than another.”
Panel auditInternal validity: medium · scope of inference: Whether network meta-analyses can reliably distinguish efficacy among new-generation antidepressants.Key limitations: simulation not clinical data · methodological critique · does not name escitalopram or sertraline specifically
4 of 18 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus offers no primary comparison supporting a class-wide 'best' ranking and multiple admissible signals contradict it, but is too thin to fully refute a nuanced ranking claim.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No admissible class-wide comparative ranking. The claim is inherently a ranking of the whole class, but the only corpus papers attempting it are excluded by study type, leaving the central question unaddressed. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An admissible head-to-head programme or primary multi-arm trial comparing escitalopram and sertraline against the major antidepressants on both response/remission and dropout.
Open question: Do escitalopram and sertraline outperform other antidepressants on efficacy when compared directly rather than versus placebo? Why it is still open: The only direct comparisons in the corpus [2][4] show no superiority, and the class-wide syntheses are excluded, so superiority is untested here.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19